- Standard Treatment
- Advance Treatment
Waldenstrom Macroglobulinemia Treatment Market size was valued at USD 486.5 million in 2022 and is expected to grow at a significant CAGR of 6.7% CAGR from 2023 to 2029. Waldenstrom Macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow, it is a type of Non-Hodgkin lymphoma, and cancer can make a large amount of abnormal white blood cells. The increase in the prevalence and incidence of increase in cases of Waldenstrom macroglobulinemia and increase in the drug development by the regulatory bodies are enhancing the market growth. Macroglobulinemia is caused by one abnormal white blood cell occur genetic testing mutation and tells cells to produce white blood continuously. The rise in the need for novel drugs is further anticipated to propel the growth of Waldenstrom macroglobulinemia medicine and provide new drugs and development in this segment. The inadequate accessibility of diseases and treatment options results from new research and development for medicine which is the major key opportunity in this market. Geographically, North America held the major market share in 2022 due to the rise of incidence cases and is expected to dominate the global Waldenstrom Macroglobulinemia market in the forecasted years.
Recent Market Key Developments:
In August 2021, the Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with waldenstrom’s macroglobulinemia (WM).
In Jan 2022, BeiGene announced the acceptance of its sNDA application in China for Brukinsa for the treatment of waldenstrom’s macroglobulinemia (WM).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The increasing prevalence of white blood cancer across the world is the major market opportunity in the Waldenstrom Macroglobulinemia Treatment Market during the forecast period. Research & development in Waldenstrom macroglobulinemia treatment is in the ongoing process new drugs are the major factor for the treatment of white blood cells cancer, and the rise in the number of cases of incidence provides a new opportunity to the key players to provide healthcare and medication of this cancer.
The Waldenstrom Macroglobulinemia Treatment Market size was valued at USD 163.7 million in 2022 and is expected to grow at a significant CAGR of 6.7% CAGR from 2023 to 2029.
The leading players in the Waldenstrom Macroglobulinemia Treatment Market are Johnson & Johnson Services, Inc, Shionogi Inc, Kyowa Kirin Co., Ltd, Innate Pharma SA, Bioniz, Eisai Co., Ltd, Minophagen Pharmaceutical Co., LTD, Bayer AG, Novartis AG, Gilead Sciences, Inc, Merck & Co., Inc, STI Pharma, LLC, Amerigen Pharmaceuticals Limited, Pfizer Inc., Takeda Pharmaceutical Company Limited., Abbott, and F. Hoffmann-La Roche Ltd.
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast is presented from 2023 – 2029.